350,000 Shares in Tyra Biosciences, Inc. $TYRA Acquired by Elmind Capital LP

Posted by Geri Gentry on Jun 18th, 2026

Elmind Capital LP bought a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 350,000 shares of the company’s stock, valued at approximately $9,202,000. Tyra Biosciences accounts for approximately 2.7% of Elmind Capital LP’s holdings, making the stock its 13th biggest position.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TYRA. Millennium Management LLC raised its holdings in Tyra Biosciences by 28.2% during the first quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock worth $3,759,000 after purchasing an additional 89,024 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Tyra Biosciences by 21.7% during the first quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock worth $725,000 after purchasing an additional 13,896 shares in the last quarter. Woodline Partners LP bought a new stake in Tyra Biosciences during the first quarter worth approximately $931,000. Jane Street Group LLC bought a new stake in Tyra Biosciences during the first quarter worth approximately $324,000. Finally, Geode Capital Management LLC raised its holdings in Tyra Biosciences by 9.8% during the second quarter. Geode Capital Management LLC now owns 567,126 shares of the company’s stock worth $5,428,000 after purchasing an additional 50,836 shares in the last quarter. Institutional investors own 84.14% of the company’s stock.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Gilla Kaplan sold 14,295 shares of Tyra Biosciences stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total transaction of $528,486.15. Following the transaction, the director directly owned 28,231 shares in the company, valued at approximately $1,043,700.07. The trade was a 33.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 12.50% of the company’s stock.

Tyra Biosciences Stock Performance

NASDAQ TYRA opened at $29.07 on Thursday. The stock has a market capitalization of $1.73 billion, a P/E ratio of -13.33 and a beta of 0.75. Tyra Biosciences, Inc. has a 1 year low of $8.98 and a 1 year high of $40.65. The business’s fifty day moving average is $33.04 and its two-hundred day moving average is $31.20.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.04). On average, research analysts forecast that Tyra Biosciences, Inc. will post -2.69 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Wolfe Research assumed coverage on Tyra Biosciences in a report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Bank of America upped their price target on Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Cantor Fitzgerald assumed coverage on Tyra Biosciences in a report on Tuesday, February 24th. They issued an “overweight” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price target on shares of Tyra Biosciences in a report on Thursday, May 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $47.00.

Get Our Latest Stock Report on TYRA

About Tyra Biosciences

(Free Report)

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.